Last updated: 2026-09-07 06:15:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arvinas, Inc. (ARVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.39, with a market capitalization of $627.05M and a P/E ratio of 65.46. Over the past 52 weeks, its price has ranged from $6.97 to $14.51. This page covers its latest market performance, valuation, price trends and company information.
$627.05M | |
$9.31 | |
$108.47 | |
$5.90 | |
$9.31 | |
330.59K | |
-- | |
65.46 | |
$14.51 | |
$6.97 | |
-- | |
-- |
Arvinas, Inc. (ARVN) last closed at $9.31 as of 2026-09-04 23:32:00, unchanged from the previous close of $9.31.
During the latest regular trading session, ARVN traded between $5.90 and $108.47, with a volume of 330.59K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Arvinas, Inc. (ARVN) moved from $9.12 to $9.39, representing a gain of 2.92% ($0.27).
The stock traded between $9.21 and $9.45 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 539.68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.0%
ARVN is currently trading at $9.39, placing it 32.0% of the way from its 52-week low of $6.97 to its 52-week high of $14.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 246 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arvinas, Inc. (ARVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.